Skip to content

Generate Biomedicines

Generate Biomedicines utilizes a generative AI platform driven by machine learning to design novel protein therapeutics from scratch, focusing on diverse therapeutic modalities.

Paid

stork
I am a flat drawing.
One flat drawing and one typed sentence.
This drawing was never animated.
A photo, a cartoon, a painting or a 3D character. From 10 cents a minute. Free to try.
Make a photo talkDevelopers: there is an API

What is Generate Biomedicines?

Generate Biomedicines is a generative AI platform tool developed by Generate Biomedicines that enables biopharmaceutical researchers and drug developers to design novel protein therapeutics from scratch. It integrates computational design with large-scale biological experimentation in a continuous 'design–build–test–learn' feedback loop.

Key Features of Generate Biomedicines

Generate Biomedicines' platform incorporates advanced AI and machine learning methodologies to facilitate the creation and optimization of therapeutic proteins.

  • Generative AI platform for de novo protein therapeutics design.
  • Machine learning-driven protein design and optimization.
  • Ability to design novel protein therapeutics from scratch.
  • Focus on diverse therapeutic modalities, including antibodies, peptides, enzymes, and cell therapies.
  • Proprietary 'Generate Platform' integrating computational design with biological experimentation.
  • AI models trained on extensive datasets, including 160,000 protein structures and 190 million genetic sequences.
  • Optimization of existing proteins for improved properties like affinity, specificity, and developability.
  • Pioneering Generative Biology® methodology.
  • Capacity to create medicines on demand with specific therapeutic functions.

Who Should Use Generate Biomedicines?

Generate Biomedicines primarily serves the biopharmaceutical industry and research institutions engaged in advanced drug discovery and development.

  • Biopharmaceutical companies seeking novel protein therapeutics for various diseases.
  • Researchers and developers focused on creating medicines across diverse modalities (e.g., antibodies, enzymes, cell therapies).
  • Organizations targeting therapeutic areas such as immunology, inflammation, oncology, and infectious diseases.
  • Drug developers aiming to address historically challenging or 'undruggable' biological targets.
  • Pharmaceutical partners interested in multi-target collaborations for drug discovery and development.

How to Use Generate Biomedicines

Generate Biomedicines operates as a clinical-stage biotechnology company, utilizing its internal platform for drug development and engaging in strategic partnerships. Direct user interaction with the platform as a software tool is not applicable.

  1. Identify specific therapeutic targets or desired protein functions for novel medicines.
  2. Utilize the Generate Platform's computational design capabilities to propose novel protein sequences and structures.
  3. Conduct large-scale biological experimentation to synthesize, build, and test the designed proteins.
  4. Integrate experimental results into the AI models for continuous learning and refinement of design principles.
  5. Iteratively optimize lead protein candidates for enhanced therapeutic properties and developability.
  6. Advance validated protein therapeutics through preclinical studies and subsequent clinical trial phases.

Generate Biomedicines Pricing & Plans

Generate Biomedicines operates on a proprietary drug development model, generating revenue through its therapeutic pipeline, strategic collaborations with pharmaceutical partners, and public market financing. It does not offer subscription plans or direct pricing for its platform as a service to external users. Collaborations typically involve upfront payments, milestone payments, and royalties.

Pros

  • Pioneering generative biology platform for de novo protein design across multiple modalities.
  • Integrated 'design–build–test–learn' feedback loop for continuous and compounding discovery.
  • Significant funding, including a $400 million IPO, supporting extensive R&D and clinical programs.
  • Multiple therapeutic programs in clinical trials, including a lead Phase 3 candidate (GB-0895).
  • Active multi-target collaborations with major pharmaceutical partners like Amgen and Novartis.
  • Potential to address historically challenging or 'undruggable' biological targets.

Cons

  • Not a direct-access software tool for individual users; primarily a drug development company.
  • Market reception for its IPO was initially 'cool,' with shares declining on the first day of trading.
  • Long development cycles and high capital requirements inherent to clinical-stage biotechnology.
  • Success is contingent on positive clinical trial outcomes and regulatory approvals.
  • The company's focus is on developing its own pipeline and partnerships, not providing a general-purpose AI platform for external use.

Generate Biomedicines vs Competitors

Generate Biomedicines distinguishes itself within the generative AI drug discovery landscape through its integrated platform and broad therapeutic focus.

Generate Biomedicines

Paid

Enjoying this? Get one like it in your inbox each morning.

one email a day · unsubscribe in two clicks · no third-party tracking